Trial Profile
A Two-part Phase I Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Target Engagement of Single Intravenous and Subcutaneous Doses of GSK3858279 in Healthy Participants and to Evaluate the Efficacy of Repeat Subcutaneous Doses in Participants With Osteoarthritis of the Knee
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs GSK-3858279 (Primary) ; GSK-3858279 (Primary)
- Indications Musculoskeletal pain
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 15 Nov 2023 Results (n=48 from Part B) assessing efficacy, safety, pharmacokinetic of repeated dosing of GSK3858279 in patients with knee osteoarthritis and immunogenicity presented at the ACR Convergence 2023
- 03 Jun 2023 Results assessing the efficacy, safety, pharmacokinetic and immunogenicity (n=48; Part B) of Gsk3858279 in patients with knee osteoarthritis, presented at the 24th Annual Congress of the European League Against Rheumatism.
- 19 Oct 2022 Status changed from active, no longer recruiting to completed.